Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.02

Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.02).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
• Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares